we discuss ideas like this as they happen in more detail. All active investors are welcome to join on a free trial and ask any question in our chat room full of sophisticated traders and investors.We continue our series with the following lines for Trinity Capital Inc. (NASDAQ: TRIN ) and its baby bonds. It is true that the whole BDC sector is under pressure, but if you look at this particular company, itDenislav leads the investing group Trade With Beta , features of the service include: frequent picks for ...

Accessibility StatementSkip Navigation PHOENIX, Oct. 21, 2025 /PRNewswire/ -- Trinity Capital Inc. (Nasdaq: TRIN) (the "Company"), a leading alternative asset manager, today announced the commitment of $15 million in growth capital to Kard Financial, Inc., ("Kard"), a commerce media network that helps fintechs and financial institutions drive usage, loyalty, and engagement through merchant-specific rewards. Kard powers next-generation rewards programs through a flexible, API-first platform that enables ...

Core Viewpoint - Trinity Capital Inc. (NASDAQ: TRIN) is positioned for potential growth, with UBS setting a price target of $17, indicating a 14.17% upside from its current price of $14.89 [1][5]. Investment Activity - TRIN has invested $130 million in Candel Therapeutics, a biopharmaceutical company focused on cancer-fighting viral immunotherapies, which may enhance TRIN's portfolio and future earnings [2][5]. Stock Performance - TRIN's stock is currently priced at $14.98, reflecting a slight increase of 1.01% with a price change of $0.15, and has shown volatility with a trading range between $14.72 and $15.015 today [3][5]. - Over the past year, TRIN's stock has fluctuated between a low of $12.50 and a high of $16.82 [3]. Market Metrics - TRIN's market capitalization is approximately $1.05 billion, indicating its size and market presence [4]. - The stock has a trading volume of 365,074 shares, demonstrating active investor interest which can influence price movements [4][5].

Core Viewpoint - Candel Therapeutics has secured a five-year, $130 million term loan facility with Trinity Capital to enhance its financial position and support the initiation of pivotal clinical trials for its lead product candidate, CAN-2409, in non-small cell lung cancer (NSCLC) and localized prostate cancer [1][2][3]. Financial Details - The loan facility consists of four tranches, with an initial draw of $50 million at closing, and an additional $80 million available based on the achievement of specific milestones [2][6]. - The interest rate on the loan is set at 10.25% per annum, with an interest-only period of 36 months, extendable for an additional 12 months upon meeting certain commercial milestones [2]. Strategic Implications - The financing will allow the company to initiate a pivotal phase 3 clinical trial of CAN-2409 in NSCLC in Q2 2026 and prepare for a potential Biologics License Application submission for prostate cancer in Q4 2026 [3][9]. - Candel Therapeutics aims to focus its resources on early localized prostate cancer and NSCLC, while seeking external partnerships for the development of CAN-2409 in pancreatic ductal adenocarcinoma (PDAC) [3][9]. Clinical Development - Candel has completed successful phase 2a clinical trials for CAN-2409 in both NSCLC and PDAC, and is advancing towards a pivotal phase 3 trial for localized prostate cancer [9]. - The company has received multiple designations from the FDA, including Fast Track and Orphan Drug Designation for CAN-2409 in various indications [9]. Company Overview - Candel Therapeutics is a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to combat cancer, with its lead product candidate being CAN-2409 from its adenovirus platform [8].

Core Insights - Trinity Capital Inc. has committed $130 million in growth capital to Candel Therapeutics, a clinical-stage biopharmaceutical company focused on viral immunotherapies for cancer treatment [1][4] Company Overview - Candel Therapeutics is developing off-the-shelf cancer treatments that utilize the patient's immune system to combat various cancers, including prostate, pancreatic, lung, and brain cancer [2][6] - The company has received multiple FDA designations for its therapies, including Regenerative Medicine Advanced Therapy Designation and Fast Track Designation for localized prostate cancer and non-small cell lung cancer [2][6] Investment Details - The investment from Trinity Capital will support the clinical development of Candel's lead therapy, CAN-2409, and activities related to its pre-commercialization and launch for prostate cancer, pending regulatory approval [3][4] - This partnership is seen as a pivotal moment for Candel, enhancing its financial position and accelerating the advancement of its innovative therapies [4] Clinical Development - Candel's CAN-2409 has completed successful phase 2a clinical trials for non-small cell lung cancer and pancreatic ductal adenocarcinoma, and is undergoing a pivotal phase 3 trial for localized prostate cancer [6] - CAN-3110, another product candidate, is currently in a phase 1b clinical trial for recurrent high-grade glioma and has received Fast Track and Orphan Drug Designations from the FDA [6] Strategic Positioning - Trinity Capital aims to deliver consistent returns through investments in growth-oriented companies across various sectors, including life sciences, having deployed over $4.7 billion across more than 420 investments since its inception [5]

Group 1 - Business development companies (BDCs) have experienced significant declines in the past month due to fears in the lending markets stemming from lower interest rates [1] - The fundamentals of most BDCs remain strong despite the market downturn [1] - The article reflects an income-oriented investment strategy focused on high-yield income sources such as BDCs, REITs, CEFs, and ETFs to enhance retirement income [1] Group 2 - The author emphasizes the importance of conducting due diligence before making investment decisions, highlighting the unpredictability of market psychology [1] - The article does not provide specific investment recommendations or advice, indicating that past performance is not indicative of future results [2]

CHARLOTTE, N.C.--(BUSINESS WIRE)--Town Lane and Trinity Capital Advisors Announce Uptown Charlotte Office Acquisition. ...

Group 1 - Business Development Companies (BDCs) are financial vehicles that aim to source capital at low costs and lend it at higher yields to businesses that cannot access traditional banking services [1] Group 2 - Roberts Berzins has over a decade of experience in financial management, focusing on helping corporates with financial strategies and large-scale financings [2] - He has contributed to institutionalizing the REIT framework in Latvia to enhance liquidity in pan-Baltic capital markets [2] - His work includes developing national SOE financing guidelines and frameworks for channeling private capital into affordable housing [2]

Core Insights - Trinity Capital Inc. has committed $45 million in growth capital to Rapid Micro Biosystems, a company specializing in automation solutions for microbial quality control in healthcare product manufacturing [1][3][5] - Rapid Micro's Growth Direct platform enhances operational efficiency and data integrity, enabling faster and more accurate results in critical applications such as environmental monitoring and sterility testing [2][5] Company Overview - Trinity Capital Inc. is an alternative asset manager focused on private credit markets, having deployed over $4.7 billion across more than 420 investments since its inception in 2008 [4] - Rapid Micro Biosystems provides automation solutions that modernize manual microbial quality control testing workflows, significantly impacting biopharma manufacturing processes [5] Strategic Goals - The new capital from Trinity Capital will support Rapid Micro's global expansion of the Growth Direct platform and drive gross margin improvements through cost reductions and increased manufacturing efficiencies [3][4] - Rapid Micro aims to strengthen its financial position and focus on long-term revenue growth, margin expansion, and shareholder value enhancement [4]

Core Insights - Trinity Capital Inc. has committed $100 million in growth capital to Angel Studios, a media and technology company focused on values-based storytelling [1][3] - Angel Studios empowers its audience of over 1.5 million members to act as virtual co-producers, influencing the production of films and television shows that promote positive values [2][4] - The recent business combination with Southport Acquisition Corporation has allowed Angel Studios to trade publicly under the ticker symbol "ANGX" [3] Company Overview - Trinity Capital Inc. is an alternative asset manager that provides access to private credit markets, focusing on growth-oriented companies across various lending verticals [3] - Since its inception in 2008, Trinity Capital has deployed over $4.7 billion across more than 420 investments [3] - Angel Studios operates as a values-based distribution company, leveraging a global community of over 1.5 million paying members to decide on film and television projects [4]